Peripheral neuropathy: zalcitabine reassessed

Area of Science:

• HIV/AIDS Research
• Pharmacology
• Infectious Diseases

Background:

• Long-term HIV management requires optimal use of all antiretrovirals.
• Zalcitabine, a nucleoside analogue reverse transcriptase inhibitor (NRTI), is underutilized.
• Peripheral neuropathy (PN) is a known potential side effect of zalcitabine.

Purpose of the Study:

• To evaluate the current clinical utility of zalcitabine in HIV treatment.
• To reassess the risk of peripheral neuropathy (PN) associated with zalcitabine in contemporary settings.

Main Methods:

• Review of clinical trial data and treatment guidelines.
• Analysis of zalcitabine's safety and efficacy profile in combination therapy.

Main Results:

• Perception of zalcitabine's poor tolerability stems from early monotherapy trials.
• Peripheral neuropathy (PN) is infrequent when zalcitabine is used in combination with other antiretrovirals.
• Current treatment settings demonstrate a more favorable safety profile for zalcitabine.

Conclusions:

• Zalcitabine remains a viable option in HIV management when used appropriately.
• The risk of peripheral neuropathy (PN) is manageable in modern combination antiretroviral therapy.
• Reevaluation of zalcitabine's role in HIV treatment is warranted based on updated evidence.